Oral Contraceptive Pills: Access and Availability
This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.
The White House announcement focused on reducing the cost of some IVF drugs and clarifying options for employers to offer standalone fertility benefits for their employees and their dependents. This policy watch examines some key takeaways about the Trump IVF plan.
This analysis explores trends in how the cost of healthcare affects access to care in the U.S. using National Health Interview Survey (NHIS) data. In 2024, about 1 in 6 adults (17%) reported delaying or not getting healthcare due to cost
This factsheet discusses HPV and related cancers, use of the HPV vaccines for both females and males, and insurance coverage and access to the vaccines.
This report examines how LGBTQ+ adults' experiences with health care costs and access compare to those of non-LGBTQ+ adults, finding that LGBTQ+ adults face significantly greater challenges affording and accessing care.
With recent federal actions to curtail vaccine access, many states have announced actions intended to maintain broader access. This issue brief provides a snapshot of this rapidly changing landscape, tracking which states have instituted changes in response to or in anticipation of administration policy changes.
In addition to ongoing litigation, last September the Trump administration FDA, after requests from anti-abortion organizations and state attorneys general, initiated an internal review of mifepristone’s safety. This adds uncertainty as the agency could revise dispensing rules independently of the courts. With the FDA commissioner’s resignation this week and no permanent leader in place, the timeline for completing the review remains unclear.
The contraceptive implant is the most effective method of birth control available, and while it’s use is still low compared to other methods, its provision and use are increasing.
This brief summarizes recent and proposed actions by states related to access to state-funded health coverage and other services for immigrants and immigration enforcement activity during the 2025 and 2026 state legislative sessions.
This analysis examines the costs, availability, and take-up of health benefits for workers with lower wages, using survey data and focus groups with more than 100 U.S. employers with over a quarter of a million employees.
© 2026 KFF